Fosun Kite and Subang Jaya Medical Centre Forge Strategic Partnership to Advance Cell Therapy in Southeast Asia

According to the Strategic Cooperation Memorandum, both parties will leverage their respective advantageous resources to engage in in-depth collaboration across three areas: cell therapy service support, clinical research cooperation, and academic exchange. This partnership aims to jointly explore efficient pathways for the research and development, regulatory registration, and clinical application of Fosun Kite’s innovative cell therapy products in Southeast Asia, thereby accelerating their market launch.

Currently, cell and gene therapy, as a frontier innovation in the biopharmaceutical sector, is embracing global development opportunities. At the policy level, continuous support is pressing the “accelerator” for industrial innovation. As a pioneer and leading enterprise in China’s cell therapy field, Fosun Kite Biotechnology Co., Ltd. has always actively responded to the national call for promoting the high-quality development of innovative drugs and building a multi-tiered medical security system. The achievement of this international cooperation marks the extension of domestic experience and capabilities in cell therapy to broader overseas markets.

SJMC is a member of Asia’s Yikang Healthcare Group and is renowned for its clinical outcomes. As a leading cell therapy enterprise in China, Fosun Kite will leverage its extensive collaborative network with top-tier Chinese hospitals and clinical experts to facilitate interactions between SJMC and leading domestic medical institutions in hematology, oncology, and other fields. This initiative aims to promote the sharing of treatment standards, clinical experience, and the latest scientific research advancements, thereby enhancing the overall level of diagnosis and treatment in the region.

The conclusion of this strategic partnership not only marks another milestone in Fosun Kite’s internationalization within the cell therapy field, but also provides a new model for global cooperation in China’s biopharmaceutical industry, jointly promoting the high-quality global development of the cell and gene therapy sector.